Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases.
It also develops CDK2 to treat ovarian, uterine, and breast cancers.
The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.29 Increased by +58.57% | -0.47 Increased by +38.42% |
| Aug 8, 24 | -0.43 Increased by +39.44% | -0.54 Increased by +20.49% |
| May 9, 24 | -0.53 Increased by +18.46% | -0.57 Increased by +7.02% |
| Mar 14, 24 | -0.58 Increased by +7.94% | -0.33 Decreased by -75.76% |
| Nov 9, 23 | -0.70 Decreased by -20.69% | -0.72 Increased by +2.78% |
| Aug 10, 23 | -0.71 Decreased by -24.56% | -0.70 Decreased by -1.43% |
| May 11, 23 | -0.65 Decreased by -27.45% | -0.68 Increased by +4.41% |
| Mar 16, 23 | -0.63 Increased by +32.26% | -0.62 Decreased by -1.61% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 9.22 M Increased by +N/A% | -23.86 M Increased by +31.60% | Decreased by -258.89% Decreased by N/A% |
| Jun 30, 24 | 4.70 M Increased by +N/A% | -30.31 M Increased by +13.84% | Decreased by -645.58% Decreased by N/A% |
| Mar 31, 24 | 1.06 M Increased by +N/A% | -31.97 M Decreased by -7.21% | Decreased by -3.00 K% Decreased by N/A% |
| Dec 31, 23 | 8.75 M Increased by +N/A% | -33.25 M Decreased by -14.37% | Decreased by -379.94% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -34.88 M Decreased by -32.77% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -35.18 M Decreased by -36.84% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -29.82 M Decreased by -26.55% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -29.07 M Decreased by -24.04% | Decreased by N/A% Decreased by N/A% |